Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats

FEBS Letters

Volumn 580, Issue 18, 2006, Pages 4337-4345

  Murillo Rodríguez, Eric ^a   Millán Aldaco, Diana ^a   Palomero Rivero, Marcela ^a   Mechoulam, Raphael ^b   Drucker Colín, René ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Anandamide; Cannabinoid receptor; Dopamine; Insomnia

Indexed keywords

ANANDAMIDE; CANNABIDIOL; CANNABIS; DOPAMINE; PROTEIN C FOS;

ALERTNESS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL ACTIVATION; CONTROLLED STUDY; DARKNESS; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTHALAMUS; LIGHT; MALE; MICRODIALYSIS; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REM SLEEP; SLEEP; WAKEFULNESS;

ANIMALS; ARACHIDONIC ACIDS; CANNABIDIOL; DOPAMINE; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; MALE; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS C-FOS; RAPHE NUCLEI; RATS; RATS, WISTAR; SLEEP; WAKEFULNESS;

ANIMALIA; CANNABIS SATIVA;

EID: 33746518572     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.04.102     Document Type: Article

References (64)

1. Grinspoon L., Bakalar J.B., Zimmer L., and Morgan J.P. Marijuana addiction. Science 277 5327 (1997) 750-752
2. Mechoulam R., Shani A., Edery H., and Grunfeld Y. Chemical basis of hashish activity. Science 169 945 (1970) 611-612
3. Mechoulam R. Marihuana chemistry. Science 168 936 (1996) 1159-1166
4. Adams I.B., and Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 11 (1996) 1585-1614
5. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 58 4 (1999) 315-348
6. Mechoulam R., and Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem. Phys. Lipids 121 1-2 (2002) 35-43
7. Grotenhermen F. Pharmacology of cannabinoids. Neuro. Endocrinol. Lett. 25 1-2 (2004) 14-23
8. McGilveray I.J. Pharmacokinetics of cannabinoids. Pain Res. Manag. 10 A (2005) 15A-22A
9. Fadda P., Robinson L., Fratta W., Pertwee R.G., and Riedel G. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47 8 (2004) 1170-1179
10. 9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J. Pharm. Pharmacol. 27 8 (1975) 608-609
11. Pickens J.T. Sedative activity of cannabis in relation to its Δ′-trans-tetrahydrocannabinol and cannabidiol content. Br. J. Pharmacol. 72 4 (1981) 649-656
12. Russo E., and Guy G.W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses 66 2 (2006) 234-246
13. Guimaraes F.S., Chiaretti T.M., Graeff F.G., and Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacol 100 4 (1990) 558-589
14. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., and Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 1-2 (2005) 96-107
15. Pivik R.T., Zarcone V., Dement W.C., and Hollister L.E. Δ-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. Clin. Pharmacol. Ther. 13 3 (1972) 426-435
16. Feinberg I., Jones R., Walker J.M., Cavness C., and March J. Effects of high dosage Δ-9-tetrahydrocannabinol on sleep patterns in man. Clin. Pharmacol. Ther. 17 4 (1975) 458-466
17. Feinberg I., Jones R., Walker J., Cavness C., and Floyd T. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin. Pharmacol. Ther. 19 6 (1976) 782-794
18. Monti J.M. Hypnotic-like effects of cannabidiol in the rat. Psychopharmacology 55 3 (1977) 263-265
19. Carlini E.A., and Cunha J.M. Hypnotic and antiepileptic effects of cannabidiol. J. Clin. Pharmacol. 21 Suppl. 8-9 (1981) 417S-427S
20. Nicholson A.N., Turner C., Stone B.M., and Robson P.J. Effect of Δ-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J. Clin. Psychopharmacol. 24 3 (2004) 305-313
21. Tanda G., Pontieri F.E., and Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276 5321 (1997) 2048-2050
22. 9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br. J. Pharmacol. 128 1 (1999) 21-26
23. van der Stelt M., and Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480 1-3 (2003) 133-150
24. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., and Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134 4 (2001) 845-852
25. Fride E., Feigin C., Ponde D.E., Breuer A., Hanus L., Arshavsky N., and Mechoulam R. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur. J. Pharmacol. 506 2 (2004) 179-188
26. Murillo-Rodriguez E., Sanchez-Alavez M., Navarro L., Martinez-Gonzalez D., Drucker-Colin R., and Prospero-Garcia O. Anandamide modulates sleep and memory in rats. Brain Res. 812 1-2 (1998) 270-274
27. Murillo-Rodriguez E., Cabeza R., Mendez-Diaz M., Navarro L., and Prospero-Garcia O. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport 12 10 (2001) 2131-2136
28. Murillo-Rodriguez E., Blanco-Centurion C., Sanchez C., Piomelli D., and Shiromani P.J. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep 26 8 (2003) 943-947
29. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, New York
30. Mechoulam R., Parker L.A., and Gallily R. Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol. 42 Suppl. 11 (2002) 11S-19S
31. Verdugo-Diaz L., Palomero-Rivero M., and Drucker-Colin R. Differentiation of chromaffin cells by extremely low frequency magnetic fields changes ratios of catecholamine type messenger. Bioelectrochem. Bioenerg. 46 (1998) 297-300
32. Garcia-Garcia F., Beltran-Parrazal L., Jimenez-Anguiano A., Vega-Gonzalez A., and Drucker-Colin R. Manipulations during forced wakefulness have differential impact on sleep architecture, EEG power spectrum, and Fos induction. Brain Res. Bull. 47 4 (1998) 317-324
33. Szymusiak R., Alam N., Steininger T.L., and McGinty D. Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res. 803 1-2 (1998) 178-188
34. Guimaraes V.M., Zuardi A.W., Del Bel E.A., and Guimaraes F.S. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 75 5 (2004) 633-638
35. Sallanon M., Kitahawa K., Buda C., Puymartin M., Luppi P.H., and Jouvet M. Effect of electrolytic lesion of hypothalamic paraventricular nucleus and its related areas on the sleep-waking cycle in the cat. Arch. Ital. Biol. 125 (1986) 305-315
36. Suntsova N.V., Dergacheva O.Y., and Burikov A.A. The role of the posterior hypothalamus in controlling the paradoxical phase of sleep. Neurosci. Behav. Physiol. 30 2 (2000) 161-167
37. Suntsova N.V., and Dergacheva O.Y. Dynamics of neuron activity in the lateral preoptic area of the hypothalamus during the sleep-waking cycle. Neurosci. Behav. Physiol. 33 7 (2003) 651-658
38. Lin J.S., Sakai K., Vanni-Mercier G., and Jouvet M. A critical role of the posterior hypothalamus in the mechanism of wakefulness determined by microinjection of muscimol in freely moving cats. Brain Res. 479 (1989) 225-240
39. McGinty D.J., and Harper R.M. Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res. 101 3 (1976) 569-575
40. Trulson M.E., and Jacobs B.L. Raphe unit activity in freely moving cats: correlation with level of behavioral arousal. Brain Res. 163 1 (1979) 135-150
41. Jones B.E. Arousal systems. Front. Biosci. 8 (2003) s438-s451
42. Russo E.B., Burnett A., Hall B., and Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30 8 (2005) 1037-1043
43. McPartland J.M., and Russo E.B. Cannabis and cannabis extracts: greater than the sum of their parts?. J. Cannabis Ther. 1 3-4 (2001) 103-132
44. Jones B.E., Bobillier P., Pin C., and Jouvet M. The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res. 58 1 (1973) 157-177
45. Rye D.B., and Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 58 3 (2002) 341-346
46. Paus S., Brecht H.M., Koster J., Seeger G., Klockgether T., and Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov. Disord. 18 6 (2003) 659-667
47. Isaac S.O., and Berridge C.W. Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J. Pharmacol. Exp. Ther. 307 1 (2003) 386-394
48. Nishino S., Mao J., Sampathkumaran R., and Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res. Online 1 1 (1998) 49-61
49. Kume K., Kume S., Park S.K., Hirsh J., and Jackson F.R. Dopamine is a regulator of arousal in the fruit fly. J. Neurosci. 25 32 (2005) 7377-7384
50. Lena I., Parrot S., Deschaux O., Muffat-Joly S., Sauvinet V., Renaud B., Suaud-Chagny M.F., and Gottesmann C. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J. Neurosci. Res. 81 6 (2005) 891-899
51. Lu J., Jhou T.C., and Saper C.B. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J. Neurosci. 26 1 (2006) 193-202
52. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., and Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21 5 (2001) 1787-1794
53. Drysdale A.J., Ryan D., Pertwee R.G., and Platt B. Cannabidiol-induced intracellular Ca(2+) elevations in hippocampal cells. Neuropharmacology 50 5 (2006) 621-631
54. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., and Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 97 17 (2000) 9561-9566
55. Parker L.A., Mechoulam R., and Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13 5 (2002) 567-570
56. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 5090 (1992) 1946-1949
57. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., and Piomelli D. An anorexic lipid mediator regulated by feeding. Nature 414 6860 (2001) 209-212
58. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313 1 (2005) 352-358
59. Merritt J.C., Crawford W.J., Alexander P.C., Anduze A.L., and Gelbart S.S. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87 3 (1980) 222-228
60. Welch S.P., and Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262 1 (1992) 10-18
61. Abrahamov A., Abrahamov A., and Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 56 23-24 (1995) 2097-2102
62. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95 14 (1998) 8268-8273
63. Mechoulam R. Recent advantages in cannabinoid research. Forsch Komplementarmed Suppl 3 (1999) 16-20
64. Teare L., and Zajicek J. The use of cannabinoids in multiple sclerosis. Expert Opin. Investig. Drugs 14 7 (2005) 859-869